{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oregovomab",
    "query": {
      "intervention": "Oregovomab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oregovomab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-06T17:22:19.278Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03162562",
      "title": "The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer of Ovary",
        "Neoplasms, Ovarian",
        "Ovarian Cancer Stage IV",
        "Ovarian Cancer Recurrent",
        "Ovarian Cancer Stage III",
        "Ovary Cancer"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-30",
      "completion_date": "2020-11-05",
      "has_results": false,
      "last_update_posted_date": "2020-12-22",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Richmond, Virginia",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03162562"
    },
    {
      "nct_id": "NCT00551265",
      "title": "Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fallopian Tube Carcinoma",
        "Primary Peritoneal Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Stage III Ovarian Cancer",
        "Stage IV Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "PROCEDURE"
        },
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2007-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-07-14",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551265"
    },
    {
      "nct_id": "NCT01959672",
      "title": "Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma",
        "Resectable Pancreatic Carcinoma",
        "Stage I Pancreatic Cancer",
        "Stage IA Pancreatic Cancer",
        "Stage IB Pancreatic Cancer",
        "Stage II Pancreatic Cancer",
        "Stage IIA Pancreatic Cancer",
        "Stage IIB Pancreatic Cancer",
        "Stage III Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "4-Dimensional Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Nelfinavir Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-09-06",
      "completion_date": "2018-12-01",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01959672"
    },
    {
      "nct_id": "NCT00034138",
      "title": "A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "oregovomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Unither Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2002-03",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2007-12-18",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Orlando, Florida • South Bend, Indiana + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034138"
    },
    {
      "nct_id": "NCT01616303",
      "title": "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "oregovomab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Quest PharmaTech Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 97,
      "start_date": "2012-06-15",
      "completion_date": "2018-10-12",
      "has_results": false,
      "last_update_posted_date": "2020-09-14",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 2,
      "location_summary": "Farmington, Connecticut • South Bend, Indiana",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01616303"
    },
    {
      "nct_id": "NCT00004064",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "oregovomab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AltaRex",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 102,
      "start_date": "1998-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-06",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 15,
      "location_summary": "Newport Beach, California • Fort Myers, Florida • Orlando, Florida + 11 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004064"
    },
    {
      "nct_id": "NCT05335993",
      "title": "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Recurrent Epithelial Cancer of Ovary",
        "Recurrent Epithelial Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Peritoneal Cancer",
        "Recurrent Carcinoma of Ovary",
        "Adenocarcinoma of Ovary"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2022-07-25",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05335993"
    },
    {
      "nct_id": "NCT00050375",
      "title": "Clinical Trial for Ovarian Cancer (OvaRex®)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "oregovomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Unither Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 354,
      "start_date": "2002-12",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2007-12-18",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 62,
      "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Verne",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050375"
    },
    {
      "nct_id": "NCT04498117",
      "title": "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Ovarian Epithelial",
        "Ovarian Neoplasms",
        "Ovarian Cancer",
        "Ovarian Serous Adenocarcinoma",
        "Fallopian Tube Neoplasms",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Serous Adenocarcinoma",
        "Peritoneal Cancer",
        "Peritoneal Carcinoma",
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Oregovomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "CanariaBio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 615,
      "start_date": "2020-08-25",
      "completion_date": "2028-08-26",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 81,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Concord, California + 70 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498117"
    },
    {
      "nct_id": "NCT00034372",
      "title": "Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "oregovomab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Unither Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 102,
      "start_date": "2000-09",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2007-12-18",
      "last_synced_at": "2026-09-06T17:22:19.278Z",
      "location_count": 12,
      "location_summary": "Newport Beach, California • Stanford, California • Orlando, Florida + 8 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034372"
    }
  ]
}